Is developing an HIV-1 vaccine possible?


Journal Article (Review)

PURPOSE OF REVIEW: This review discusses select recent data that suggest that indeed it is possible to make a clinically useful preventive vaccine for HIV-1 and outlines some of the remaining obstacles that stand in the way of success. RECENT FINDINGS: Passive protection studies, with broad neutralizing antibodies for mucosal simian-HIV challenges, in nonhuman primates have suggested that lower doses of neutralizing antibodies than previously thought may be effective in preventing HIV-1 infection. The use of recombinant antibody technology coupled with the ability to culture single memory B cells has yielded new broad neutralizing antibodies and new targets for vaccine design. The success of the RV144 Thai HIV-1 efficacy trials with a replication-defective recombinant canarypox vector (ALVAC)/gp120 prime, clade B/E recombinant gp120 protein boost showing 31% efficacy has given hope that indeed a protective HIV-1 vaccine can be made. SUMMARY: Recent data in the last year have provided new hope that a clinically useful preventive HIV-1 vaccine can potentially be made. The path forward will require development of improved immunogens, understanding the correlates of protection to HIV-1, and development of immunogens to induce antibodies that can prevent the initial stages of HIV-1 infection at mucosal sites, in order to improve on the RV144 trial results.

Full Text

Duke Authors

Cited Authors

  • Haynes, BF; Liao, H-X; Tomaras, GD

Published Date

  • September 2010

Published In

Volume / Issue

  • 5 / 5

Start / End Page

  • 362 - 367

PubMed ID

  • 20978375

Pubmed Central ID

  • 20978375

Electronic International Standard Serial Number (EISSN)

  • 1746-6318

Digital Object Identifier (DOI)

  • 10.1097/COH.0b013e32833d2e90


  • eng

Conference Location

  • United States